Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd Performance

Day's Price Range
52-Week Price Range
1 Month Return-12.03 %
3 Month Return-24.03 %
1 Year Return-48.82 %

Syncom Formulations (India) Ltd Valuation

Syncom Formulations (India) Ltd in the last 5 years

Lowest (3.98x)

March 12, 2020

Today (27.86x)

March 20, 2023

Highest (81.74x)

January 18, 2022



Price to Earnings TTM Ratio

Insights on Syncom Formulations India Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    Revenue Rich

    Revenue is up for the last 3 quarters, 54.38Cr → 59.36Cr (in ₹), with an average increase of 4.3% per quarter


    Best in 3 Years

    In the last 3 years, SYNCOMF has outperformed top 5 stocks with highest market-cap in Pharmaceuticals


    Profit Spike

    Netprofit is up for the last 2 quarters, 3.59Cr → 4.14Cr (in ₹), with an average increase of 13.3% per quarter

  • imgNO EFFECT

    Against Peers

    In the last 1 year, Dr Reddys Laboratories Ltd has given 9.7% return, outperforming this stock by 55.2%

  • imgNO EFFECT

    Promoter Holding Unchanged

    Promoters holdings remained unchanged at 50.57% of holdings in Dec 2022 quarter

  • imgNO EFFECT

    Retail Holding Unchanged

    Retail Investor holdings remained unchanged at 49.43% of holdings in Dec 2022 quarter


    Price Dip

    In the last 6 months, SYNCOMF stock has moved down by -31.3%

Syncom Formulations (India) Ltd Shareholding Pattern

InvestorsHoldings %Prev. 4 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Syncom Formulations (India) Ltd Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Corporate Announcements

  • Syncom Formulations (India) Ltd Earnings Results

    Syncom Formulations (India) Ltd’s net profit jumped 3.24% since last year same period to ₹4.14Cr in the Q3 2022-2023. On a quarterly growth basis, Syncom Formulations (India) Ltd has generated 15.32% jump in its net profits since last 3-months.

    Read More
  • Syncom Formulations (India) Ltd Dividends August,2022

    In the quarter ending September 2022, Syncom Formulations (India) Ltd has declared dividend of ₹0.03 - translating a dividend yield of 0.5%.

    Read More

Syncom Formulations (India) Ltd Company Information

Incorporated as a private limited company in 1988 Syncom Formulations India was converted into a public limited company in Jun.92. The company set up a manufacturing facility at Palghar Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.89. Promoters are Kedarmal Bankda Vijay Kumar Bankda and Ajay Kumar Bankda.In addition to pharmaceutical formulations in the form of tablets capsules liquids and dry powders the company also manufactures injectibles and ear/eye drops on a loan licence basis.In 1994 the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur Madhya Pradesh. The project which was financed through a public issue made in Jan.94 was completed in 1995.During the year 199798 the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.During the year 199899 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100.During the year 19992000 the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine Ghana Kenya Tanzania Nigeria in Africa Azberjan Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products the company is aggressively manufacturing and marketing its herbal products like Edicare Attom Megacaps Ecziguard and Yas antacid salt.

Syncom Formulations (India) Ltd Share Price: ₹6.05 per share as on 22 Mar, 2023 04:01 PM
Syncom Formulations (India) Ltd Market Capitalisation: ₹705.00Cr as of today
Syncom Formulations (India) Ltd Revenue: ₹59.36Cr as on December 2022 (Q4 22)
Syncom Formulations (India) Ltd Net Profit: ₹4.14Cr as on December 2022 (Q4 22)
Syncom Formulations (India) Ltd Listing date: 11 Mar, 1994
Syncom Formulations (India) Ltd Chairperson Name: Kedarmal Bankda
OrganisationSyncom Formulations (India) Ltd
E-voting on sharesClick here to vote

Frequently Asked Questions

Syncom Formulations (India) Ltd(SYNCOMF) share price today is ₹6.05 (last updated 22 Mar, 2023 at 04:01 PM)

  • Today’s highest price of Syncom Formulations (India) Ltd(SYNCOMF) is ₹6.30.
  • Today’s lowest price of Syncom Formulations (India) Ltd(SYNCOMF) is ₹5.95.
  • (last updated 22 Mar, 2023 at 04:01 PM)
Today’s traded volume of Syncom Formulations (India) Ltd(SYNCOMF) is 1055895.
Today’s market capitalisation of Syncom Formulations (India) Ltd(SYNCOMF) is ₹705.00Cr.
Syncom Formulations (India) Ltd(SYNCOMF)Price
52 Week High₹11.60
52 Week Low₹5.80
  • (last updated 22 Mar, 2023 at 04:01 PM)
  • Syncom Formulations (India) Ltd(SYNCOMF) share price is ₹6.05 (last updated 22 Mar, 2023 at 04:01 PM). It is down -47.84% from its 52 Week High price of ₹11.60
    Syncom Formulations (India) Ltd(SYNCOMF) share price is ₹6.05 (last updated 22 Mar, 2023 at 04:01 PM). It is up 4.31% from its 52 Week Low price of ₹5.80
    Syncom Formulations (India) Ltd(SYNCOMF)Returns (%)
    1 Day Returns0.00%
    1 Month Returns-12.03%
    1 Year Returns-48.82%
    3 Year Returns891.53%
    5 Year Returns383.47%
    Syncom Formulations (India) Ltd(SYNCOMF) share price is ₹6.05 and its price to earning (PE) is 27.86. A high PE ratio indicates that a share price is overvalued, or investors are expecting a high growth rate in the future.

    Indian stocks brokerage services are provided by INDmoney Private Limited. INDmoney Private Limited is carrying out the business of in respect to stock broking activities and also carries out the activities of depository participant. SEBI Registration No. INZ000305337 | SEBI Depository Participant Registration No. IN-DP-690-2022 Depository Participant ID: CDSL 12095500 | Trading and Clearing Member of NSE (90267, M70042) and BSE (6779)

    Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are exemplary and not recommendatory. Past performance is not indicative of future returns.